Table 2.
Clinical and treatment characteristics of patients by HIV status
| Characteristic | HIV-infected (n = 96 [67%]) | HIV-uninfected (n = 47 [33%]) | P |
|---|---|---|---|
| Cervical cancer histology | .29 | ||
| Adenocarcinoma | 7 (7.3) | 6 (12.8) | |
| Squamous cell carcinoma | 89 (92.7) | 41 (87.2) | |
| Disease stage | .04 | ||
| I (IA, IB) | 14 (14.9) | 3 (6.4) | |
| II (IIA, IIB) | 57 (60.6) | 24 (51.1) | |
| III (IIIA, IIIB) | 23 (24.5) | 18 (38.3) | |
| IV | 0 (0) | 2 (4.3) | |
| Symptoms at presentation | |||
| Vaginal bleeding | 66 (68.8) | 28 (59.6) | .28 |
| Post coital bleeding | 35 (36.5) | 12 (25.5) | .19 |
| Vaginal discharge | 69 (71.9) | 35 (74.5) | .74 |
| Pelvic/back pain | 70 (72.9) | 28 (59.6) | .11 |
| Bowel/bladder | 5 (5.2) | 2 (4.3) | .80 |
| Edema | 3 (3.1) | 7 (14.9) | .01 |
| Baseline laboratory values | |||
| Creatinine (μmol/L) | 50 (41-57) | 54 (47-62) | .02 |
| Hemoglobin (g/dL) | 10.6 (9.2-12.1) | 11.3 (10.5-13) | .04 |
| ANC (×109/L) | 3.55 (2.50-6.67) | 4.63 (3.01-6.36) | .35 |
| WBC count (×109/L) | 5.77 (4.29-8.85) | 6.83 (4.75-8.91) | .49 |
| Baseline performance status (KPS) | .18 | ||
| ≥90 | 66 (68.8) | 27 (57.4) | |
| <90 | 30 (31.2) | 20 (42.6) | |
| HIV characteristics | |||
| CD4 (cells/μL) | 481 (351-579) | - | |
| CD4 category | |||
| ≥500 | 40 (47.1) | ||
| ≥350-<500 | 24 (28.2) | ||
| <350 | 21 (24.7) | ||
| On ART | 92 (95.8) | - | |
| Months on ART | 84 (24-120) | ||
| Treatment characteristics | |||
| No. of chemo cycles received | 4 (3-5) | 4 (2-4) | .45 |
| No. of chemotherapy cycles completed | .40 | ||
| 1 | 10 (10.4) | 4 (8.5) | |
| 2 | 8 (8.3) | 9 (19.2) | |
| 3 | 22 (22.9) | 9 (19.2) | |
| 4 | 29 (30.2) | 15 (31.9) | |
| 5 | 27 (28.1) | 10 (21.3) | |
| ≥4 | 56 (58.3) | 25 (53.2) | .56 |
| Received EBRT dose ≥45 Gy | 95 (99.0) | 45 (95.7) | .21 |
| Received brachytherapy dose ≥20 Gy | 73 (76.0) | 32 (68.1) | .31 |
| EQD2 (Gy) | |||
| Median (IQR) | 79.8 (74-79.8) | 79.8 (68.8-79.8) | .90 |
| Mean (standard deviation) | 75.6 (8) | 74.7 (10) | |
| Treatment duration (d) | 45 (41-52) | 48 (42-54) | .34 |
| Tumor response | .39 | ||
| Complete | 44 (45.8) | 20 (42.6) | |
| Partial | 12 (12.5) | 3 (6.4) | |
| Not available | 40 (41.7) | 23 (51.1) |
Abbreviations: ANC = absolute neutrophil count; ART = antiretroviral therapy; EBRT = external beam radiation therapy; EQD2 = radiobiological equivalent dose; KPS = Karnofsky performance score; WBC = white blood cells. Other abbreviation as in Table 1.
Values are presented as number (percentage) or median (interquartile range), unless otherwise noted.